ScienHub

People attending a scientific conference Test tubes in a lab tray People attending a conference

We enable the scientific community to achieve excellence

At ScienHub we offer comprehensive solutions for the implementation of clinical research and knowledge transfer. We accompany the scientific community in all phases of its specialized work, ensuring the quality and effectiveness of the results obtained.

Units

  • ScienHub
    Research Support

    Unit specialized in the management and development of clinical studies. We promote research by offering comprehensive support in the management and implementation of projects, ensuring their quality and offering maximum reliability of the results obtained.

  • ScienHub
    Education

    Unit dedicated to the dissemination and knowledge transfer in the medical and scientific field. We promote the professional growth of the scientific community by creating spaces to share and expand knowledge.

ScienHub in 2023

  • ScienHub

    Support to multiple therapeutic areas

    • Cardiology
    • Covid-19 and Long-Covid
    • Dermatology
    • Gastroenterology
    • Immunology
    • Nephrology
    • Oncology
    • Rheumatology
    • Urology
    • HIV
  • Education

    +50
    activities

    We have offered a wide variety of courses, conferences, congresses and webinars in all formats (face-to-face, hybrid and online).

  • Education

    +3.180
    attendees

    The professionals who attended our training activities in 2023 were primarily specialist doctors (27.1%), followed by primary care physicians (15.1%), and students (13.3%).

  • CRO

    60
    studies managed

    From the Contract Research Organization (CRO), we have managed 23 clinical trials, 20 research projects, 10 investigations involving medical devices, 4 cohorts, and 3 observational studies with pharmaceuticals.

  • Test tubes in a tray
  • CTU

    59
    studies implemented

    From the Clinical Trials Unit (CTU), we have implemented 59 clinical studies: 4 of them were Phase I and II, and the rest were Phase III and IV trials, as well as cohorts.

  • ScienHub in 2023

  • ScienHub

    Support to multiple therapeutic areas

    • Cardiology
    • Covid-19 and Long-Covid
    • Dermatology
    • Gastroenterology
    • Immunology
    • Nephrology
    • Oncology
    • Rheumatology
    • Urology
    • HIV
  • Education

    +50
    activities

    We have offered a wide variety of courses, conferences, congresses and webinars in all formats (face-to-face, hybrid and online).

  • Education

    +3.180
    attendees

    The professionals who attended our training activities in 2023 were primarily specialist doctors (27.1%), followed by primary care physicians (15.1%), and students (13.3%).

  • CRO

    60
    studies managed

    From the Contract Research Organization (CRO), we have managed 23 clinical trials, 20 research projects, 10 investigations involving medical devices, 4 cohorts, and 3 observational studies with pharmaceuticals.

  • Test tubes in a tray
  • CTU

    59
    studies implemented

    From the Clinical Trials Unit (CTU), we have implemented 59 clinical studies: 4 of them were Phase I and II, and the rest were Phase III and IV trials, as well as cohorts.

  • Revolution 2025: Breakthroughs and Challenges in HIV with Alejandro Gaviria, Former Minister of Health of Colombia

    This February, we co-organized, together with the Fight Infections Foundation, the second edition of the Revolution conference, coordinated by Drs. Boris Revollo and Arkaitz Imaz, which brought together experts to discuss the advances and challenges in the treatment and prevention of HIV. Among the speakers was Alejandro Gaviria, former Minister of Health of Colombia, who shared his experience on the democratization of access to treatments and the financial sustainability of healthcare systems in middle and low-income countries.

    Alejandro Gaviria, who led the Ministry of Health and Social Protection of Colombia for six years, highlighted the importance of ensuring equitable access to medications and managing technological pressure, a key challenge for health equity. He also emphasized the bioethical dilemmas he faced as a minister, stressing that many of the challenges in healthcare sustainability stem from decisions on treatment financing. For him, these debates should play a central role in public discussion.

    Read the full article
  • ScienHub and Its Key Role in the SUPERNOVA Study on Preventive Monoclonal Antibodies Against COVID-19

    The SUPERNOVA study evaluates the efficacy of preventive monoclonal antibodies against SARS-CoV-2 in patients with antibody synthesis deficiencies, whether due to primary causes or secondary to biological or immunosuppressive treatments.

    ScienHub’s contribution to this study has been essential, as it was responsible for coordinating and executing all procedures, as well as conducting thorough follow-ups over the course of a year through weekly phone calls to assess the onset of COVID-19 symptoms in enrolled patients. With 30 participating patients, our center was the second most active hospital in Spain in terms of participation.

    Approval of Sipavibart

    Recently, AstraZeneca announced the approval of sipavibart (AZD3152) in Europe and Japan for the prevention of symptomatic COVID-19 in immunocompromised populations, based on the results of the SUPERNOVA study.

    These findings reinforce ScienHub’s crucial role in advancing preventive strategies for vulnerable populations and highlight the importance of clinical research in the fight against COVID-19.

  • ScienHub Research Support Develops the Thalassa 2.0 Trial for Long COVID

    The Fights Infections Foundation and PharmaMar have launched the Thalassa 2.0 trial to evaluate the efficacy of plitidepsin in patients with long COVID. ScienHub Research Support will oversee the study’s execution with patients from the Hospital Universitari Germans Trias i Pujol, in collaboration with IrsiCaixa.

    The phase II study will include 90 patients divided into three groups: one will receive plitidepsin in four cycles, another will receive two cycles of placebo followed by two of plitidepsin, and the third will receive only a placebo.

    Primary objective: Assess health changes using the PROMIS-29® system.
    Secondary objective: Analyze the safety and tolerability of plitidepsin.

    This project strengthens ScienHub’s commitment to researching innovative treatments.

  • Launch of Soc Recerca: the new platform that connects volunteers with clinical trials

    We are pleased to announce the launch of Soc Recerca, the ScienHub Research Support platform designed to recruit volunteers interested in participating in clinical trials. Its mission is to drive clinical medical research and contribute to the advancement of global health.

    The importance of Soc Recerca lies in its ability to accelerate the recruitment of volunteers, a crucial factor for the success of clinical trials. The platform not only informs participants about the objectives of each study but also enables a more organized and efficient selection process, fostering more inclusive and participatory research.

    Learn more
0
    0
    Your Cart
    Your cart is emptyReturn to Shop